- Open Access
Allometric scaling of dietary linoleic acid on changes in tissue arachidonic acid using human equivalent diets in mice
Nutrition & Metabolism volume 8, Article number: 43 (2011)
It is hypothesized that dietary linoleic acid (LA) promotes chronic and acute diseases in humans by enriching tissues with arachidonic acid (AA), its downstream metabolite, and dietary studies with rodents have been useful for validation. However, levels of LA in research diets of rodents, as published in the literature, are notoriously erratic making interspecies comparisons unreliable. Therefore, the ability to extrapolate the biological effects of dietary LA from experimental rodents to humans necessitates an allometric scaling model that is rooted within a human equivalent context.
To determine the physiological response of dietary LA on tissue AA, a mathematical model for extrapolating nutrients based on energy was used, as opposed to differences in body weight. C57BL/6J mice were divided into 9 groups fed a background diet equivalent to that of the US diet (% energy) with supplemental doses of LA or AA. Changes in the phospholipid fatty acid compositions were monitored in plasma and erythrocytes and compared to data from humans supplemented with equivalent doses of LA or AA.
Increasing dietary LA had little effect on tissue AA, while supplementing diets with AA significantly increased tissue AA levels, importantly recapitulating results from human trials.
Thus, interspecies comparisons for dietary LA between rodents and humans can be achieved when rodents are provided human equivalent doses based on differences in metabolic activity as defined by energy consumption.
As surrogates for human inquisition, animal models reside at the core of medical innovation. Through careful environmental control, these genetically similar models facilitate therapeutic advancements in the magnitude of human disease. Rodent dietary composition is of particular interest in the field of nutrition research as it provides a way to assess the translational ability of individual dietary constituents, through appropriate dosing of nutrients, to physiological effects observed in humans consuming similar levels of nutrients.
Dietary profiles of n-6 polyunsaturated fatty acid (PUFA), linoleic acid (LA) and the relationship to chronic and acute diseases, in both rodents and humans, appears to lie in tissue enrichment of the downstream metabolite, arachidonic acid (AA) [1–3]. It is hypothesized that metabolism of dietary AA produces bioactive compounds called eicosanoids that are positively correlated with the appreciation of tissue AA . While the relationship of AA and eicosanoids is well established, the response to dietary LA on changes in tissue levels of AA, within the context of a human equivalent diet, remains inconclusive.
The inconsistent use of n-3 and n-6 essential fatty acids (EFAs) in the background of rodent diets is pervasive in the literature [5–10]. These EFAs are important components of the Western diet and can impact the AA phospholipid pool when absent or provided at insufficient quantities in the diet. Despite suggestions otherwise, a systematic review of the human literature reports that increases in dietary LA do not appear to significantly modify AA levels in phospholipids of plasma/serum or erythrocytes when supplemented to standard Western diets . Therefore, if precise physiological nutrient translation of fatty acids is desired, it may be important for dietary aspects of the rodent model to bear firm resemblance to human dietary components.
This study was designed to investigate a putative standard for allometric scaling with regards to an animal dietary design as it relates to the relationship between dietary LA and tissue AA. This is the first study to examine the physiological response of dietary LA on changes in AA levels in plasma/serum or erythrocyte phospholipids when provided at human equivalent supplemental doses within the context of a Western background diet, based on a percentage of energy (i.e., metabolic activity). We further investigated the potential contribution of dietary AA on tissue AA content within the context of a Western-type diet. This mathematical model using a surrogate of metabolic activity instead of differences in BW for allometric scaling should better equate interspecies translation and accommodate the differences in metabolic disparity between rodents and humans.
Sixty-two C57BL/6J male mice (Harlan Laboratory, Indianapolis, IN), 6-7 weeks of age, were randomly assigned to nine dietary groups; 5-7 animals per group were housed 2-3 animals per cage in a temperature controlled room with a 12 hr light-dark cycle. Prior to sacrifice, animals were fasted overnight. All animal procedures were approved by the University of Tennessee Animal Care and Use Committee in accordance with NIH guidelines.
All animals were maintained on a control diet for one week prior to being transferred to one of the experimental diets or maintained on the control diet. The control diet was based on a US17 Monsanto diet with slight modifications in macronutrient distributions (Table 1). The diet was designed to mimic the Western diet with the following distribution (% of energy): protein 16%, carbohydrates 50% and lipids 34% (Research Diets, New Brunswick, NJ) . Within the lipid fraction, saturated, monounsaturated and polyunsaturated fats were designed to be provided at 13%, 14% and 7% of energy, respectively. The polyunsaturated fats LA, ALA, AA and EPA+DHA were provided at 6%, 0.6%, 0.07% and 0.1% of energy, respectively. These levels are similar to those suggested in the literature for humans on a Western diet [12, 13] and/or supported by the DRIs for median daily intakes . AA and EPA+DHA were provided as ethyl esters (NuChek Prep, Elysian, MN). Experimental diets remained isocaloric and were formulated using the control diet as the background diet containing LA at ~6% of energy with additional adjustments in LA content (-2%, +2%, +4%, +6%, +8% of energy) with the addition (or subtraction) of sunflower oil (70% w/w LA) at the expense of cocoa butter, palm and trisun oils based on the ratios found in the control diet. The diets supplemented with AA were adjusted at the expense of cocoa butter.
Water and food were provided ad libitum for 21-25 days. Fresh diets were provided daily and uneaten food was discarded to minimize oxidation prior to consumption. Fatty acid analysis of the diets is presented in (Table 2).
Fatty acid analysis
Animals were randomized on a 5 day sacrifice cycle. Following 21-25 days on the experimental and control diets, 0.5-1.0 ml of whole blood was collected via cardiac puncture under anesthesia (isofluorane inhalation) using a tuberculin syringe with a 25 gauge needle containing an anticoagulant (3.8% trisodium citrate). Whole blood was centrifuged at 660 × g for 4 min at room temperature for separation of plasma and a pellet that was predominately erythrocytes, where each fraction was subjected to lipid extraction. Three ml of chloroform-methanol (1:2, v/v) were added to each fraction, and lipids were extracted with chloroform (1 ml) plus saline (1 ml), followed by chloroform (1 ml) (2×). The pooled chloroform extracts were evaporated and resuspended in a small amount of chloroform (~25 μL), and phospholipids were separated via thin layer chromatography (TLC) using HPTLC plates precoated with silica gel 60 (Merck, Darmstadt, Germany) using a chloroform-methanol (8:1, v/v) solvent system. The phospholipids were recovered from the TLC plates and saponified in 0.5 N NaCl and in the presence of BF3 in methanol at 86°C. Fatty acid methyl esters were extracted with equal volumes of hexane (2×) and evaporated under nitrogen. Fatty acid methyl esters were resuspended in hexane and analyzed by gas chromatography with a Hewlett-Packard 5880 gas chromatograph (Rochester, NY) using a DB23 capillary column (0.25 mm × 30 m) (J and W Chromatography, Folsom, OH) with hydrogen as the carrier gas, with temperature programming from 160°C to 250°C at 3.5°C/min The internal standard 1,2 diheptadecanoyl-sn-glycero-3-phosphocholine (17:0) (Avanti Polar Lipids, Alabaster, AL) was added to each sample prior to lipid extraction. The fatty acid methyl esters were identified by comparing the retention times with those of known standards (NuChek Prep, Elysian, MN). The fatty acids are presented as mole %.
Phospholipid fatty acid content in plasma and erythrocytes were compared across treatment groups using a one-way analysis of variance (ANOVA), followed by Tukey's Honestly Significant Difference (HSD) post-hoc test to determine significant differences between groups. All data were tested for normality, homogeneity of variance, and for outliers. The data were evaluated by SPSS 18 statistical package (University of Tennessee, Knoxville, TN). Data was considered significant at p < 0.05.
Food intake and weight gain were not statistically different between dietary groups (data not shown).
Fatty acid composition of plasma phospholipids
The composition of oleic acid and LA in plasma phospholipids tended to reflect differences in dietary levels of these fatty acids; however, much of these effects were not statistically significant (Figure 1 and Table 3). The dietary group with the lowest levels of LA and highest levels of oleic acid (group 1) had the lowest levels of LA and highest levels of oleic acid in the plasma phospholipids, respectively. The levels of AA did not change in any of the groups with increasing or decreasing levels of dietary LA (Table 3). DHA levels were not different among groups, with the exception of group 5. When AA was supplemented to the diets, tissue AA levels progressively increased in a dose responsive manner at the expense of LA (Figure 2 and Table 4), but tissue DHA levels did not change. A summary of the effects of LA and AA supplementation are provided in (Figure 1 and Figure 2), respectively.
Fatty acid composition of erythrocyte phospholipids
The composition of oleic acid and LA in the phospholipids of erythrocytes reflected differences in dietary levels of these fatty acids where LA supplementation significantly increased LA in the tissues (Table 5 and Figure 3). Levels of dihomo-gamma-linolenic acid (20:3n-6) and AA were unaffected by changes in dietary LA. Similarly, DHA content in erythrocytes were unaffected by changes in LA intake. When AA was supplemented in the diets, erythrocyte AA content, as well as that of its metabolites 22:4 n-6 and 22:5 n-6 progressively increased primarily at the expense of LA, but reductions in dihomo-gamma-linolenic acid were also observed (Table 6 and Figure 4). DHA levels were not reduced with increasing levels of dietary AA.
Comparison of LA and AA data in the mouse to similar data generated in human clinical trials
When the mouse data for LA was plotted against similar data generated in human clinical trials based on % energy , the results were similar between species (Figure 5). When the mouse data for AA was plotted against similar data generated in human clinical trials based on % energy , the changes in AA levels in the mice resembled the human data at the two lowest doses but not at the highest dose (Figure 6).
Animal models are not intended to replace humans, but be a substitute that is often better controlled and better able to answer narrow research questions that could not be done, on a practical basis, with humans. A common challenge faced by nutrition researchers who are interested in interspecies comparisons is identifying an appropriate background diet and appropriate doses for supplemented nutrients. In order to make these choices, studies have to be performed that can demonstrate human equivalent responses to ensure translation between species. Without these fundamental studies, no guidelines can be formulated governing scientific justification for dosing when extrapolation to humans is desired. Currently, no guidelines exist for appropriate dosing of dietary PUFAs for experimental models (i.e., mice, rats) as they relate to humans and their intakes. As such, the overall objective of this research was to determine the extent to which supplementation of human equivalent doses of LA and AA changed tissue AA content within the context of a Western-type diet using a common experimental rodent model. These results were then compared to similar data generated from clinical trials with increasing and decreasing levels of dietary LA . This is the first known study of its kind.
Interspecies relationships of body mass and mammalian physiology have been explored for over a century where various aspects of metabolism are proportional to an exponent of body weight (Wn), with "n" being between 0.67 and 0.75 [15–18]. Interspecies comparisons with regards to energetics were in part pioneered by Brody and Kleiber where they described the non-linear relationship between metabolic rate and body mass as it relates to allometric scaling (as reviewed by ). They described the concept that the relationship between metabolic rate (MR) and body weight could be linearized with the following equation: MR = a(Wn) (where "a" is a proportionality constant, "W" is in Kg and "n" is an exponent between 0.70 and 0.75). More recently, Rucker and Storms (2002) elegantly described the pitfalls of using differences in body weight as a means of making interspecies extrapolations for micronutrients because of these non-linear relationships . They addressed the appropriateness of several mathematical approaches to extrapolate nutrient intake between mice and humans and suggested food (energy) intake rather than body weight should be used to extrapolate nutrients for interspecies comparisons [20, 21]. Interestingly, when this concept was applied to a variety of standardized semi-purified diets (i.e., AIN76A, AIN93G, AIN93M), extrapolations of the micro- and macronutrients (i.e., PUFA) better mimicked recommended intakes (i.e., the DRIs) when based on energy differentials as compared to body weight (Table 7 and Table 8). This provided the rationale, if not a scientific justification, for the background diet and doses used in this study.
With this in mind, we generated a "human equivalent" background diet where the macronutrient composition mimicked that of the human diet when based on energy (Table 9) and evaluated the impact of dietary LA (4%-14% of energy) and AA (0.08%-1.35% of energy) on changes in tissue AA levels in plasma and erythrocyte phospholipids. These amounts translate into human equivalent levels of 9-31 g/d and 0.18-2.7 g/d of LA and AA, respectively, and are within those ranges reported in the DRIs for humans and/or used in clinical trials [14, 22]. Importantly, as opposed to rodent diets that selectively provide only one or two of the essential fatty acids (EFAs) (i.e., corn oil or soybean oil based diets), our background diet contained all the major n-6 and n-3 PUFAs found in the human diet (i.e., LA, ALA, AA and long chain n-3 PUFA). This is critical as all of these fatty acids are found in the Western diet and can have an impact on tissue AA levels. For this reason, there has been great interest placed upon n-6 PUFA metabolism, particularly when all EFAs are sufficiently provided in the diet at human equivalent levels.
The rodent model has been the superior target for investigation of specific fatty acids and downstream metabolites on tissue fatty acid composition since 1963 when Mohrhauer and Holman explored the metabolism of dietary EFAs . In this classic and highly cited paper, rodents were initially fed a fat-free diet (i.e. with the exclusion of all EFAs) prior to supplementation with LA (ethyl linoleate) up to 5% from energy, where a 721% increase in liver AA composition was observed with the highest doses. Other studies recapitulated these earlier results when LA was provided to a background diet that lacked nearly all or completely all n-3 and n-6 PUFAs [9, 10]. When LA was increased from nearly 0% of energy to 6-7% of energy in rodents, liver AA composition increased 173%-518% [6, 8]. Increasing LA from 6% of energy to 27% of energy (or a human equivalent dose of 59 g/d) resulted in a 134% increase in tissue AA composition . The addition of LA at supra-physiological doses (i.e., 17.3% of energy) from a background diet containing 7% LA, increased AA content by 375% when no other EFAs were provided . However, when more moderate levels of LA were supplemented to a diet containing human equivalent levels (i.e., 6.6% to 13.2% of energy), AA content in liver phospholipids increased a modest 6% . Notably, tissues have a requirement for unsaturated fatty acids for structural function and to help maintain membrane fluidity. When animals are fed a diet that exclusively contains a single PUFA (i.e., LA), its selective and robust conversion to a more highly unsaturated form is not surprising. These findings underscore the differential impact of dietary LA in rodent diets on changes in tissue AA content when the background diet is devoid of LA and/or other PUFAs, or providing LA at doses approaching pharmacological levels.
What is an appropriate background diet in rodents and what is an appropriate dose of LA that has translational ability to humans? This would be dependent upon the human literature; that is, what is the effect of LA on changes in tissue AA in individuals consuming a typical Western diet? The DRI (observed median intakes in the US population) for LA is 12 g/d and 17 g/d for women and men, respectively (approximately 6% of energy) . In a recent review of the literature, decreasing LA content in the diet up to 90% or increasing the levels up to 550% was not associated with changes in AA content in the phospholipid pools of human plasma/serum (see Figure 5) or erythrocytes . It is not unreasonable to think that with a background diet containing LA, ALA, AA, and long-chain n-3 PUFAs (i.e., EPA and DHA) at typical intakes, modifying LA levels may not influence tissue AA levels in these populations. Hence, in order to establish a human equitable response to dietary LA on tissue AA composition in the rodent model, it seems best accomplished when all EFAs are present in the diet, especially for results that are expected to translate proportionally to humans.
Increasing LA from 0% to 2% of energy replete tissue pools of n-6 PUFAs by increasing AA phospholipid concentrations . Intake of LA above 2-3% of energy in humans is not reportedly accompanied by an increase in AA content in plasma or erythrocyte phospholipids [22, 24–29], results consistent with our data. Poor conversion rates in humans would account for these results where the estimated fractional conversion of LA to AA in adults was between 0.3% and 0.6% . In rodents, tracer kinetic analysis demonstrated greater efficiency of C20 fatty acids in conversion to downstream end-products relative to C18 precursors . This would imply that feedback inhibition of Δ-6 desaturase, the rate limiting step in the conversion of LA to AA, may be responsible. Likewise, the present study reports no significant alteration in plasma/serum or erythrocyte AA phospholipids at the lowest supplemental dose of LA (4% of energy) or the highest supplemental dose (14% of energy). These results are supported by prior rodent dietary studies supplementing LA at similar levels (6.8% and 8.7% of energy) to a background diet already containing LA (4.5% of energy) [32, 33]. Hence, supplementation of HEDs of LA to a background rodent diet consisting of all EFAs found in the human diet (including LA and AA), results in changes in tissue AA content that more accurately reflect those measured in humans consuming similar levels [22, 24–26, 29].
Additionally, our data demonstrate the observable inverse relationship of dietary AA and changes in tissue LA within the rodent model. When AA was supplemented to rodents consuming a Western-like diet, tissue AA content increased in a dose dependent manner, suggesting the lack of changes with LA supplementation was not due to saturation of AA in the phospholipid pools analyzed. Likewise, when dietary AA was provided to rodents (mice, hamsters) at 1.5-4% of energy, AA content in hepatic phospholipids increased 21-80%; [12, 32–34]. Similar results were observed in intestines, macrophages, lung, heart, spleen, kidneys, testes and platelets [12, 32, 33]. These results are comparable to humans ; however, the response in rodents is more modest than that observed in humans supplemented with AA at the highest dose (see Figure 6) . The estimated human intake for AA is <200 mg/day . Our highest supplemented dose of 1.35% of energy (or a HED of 3 g/d) increased phospholipid AA levels in plasma/serum by 40%, while providing a dose of 0.75-1.5 g/d in humans increased tissue AA content by ~85% [35, 36] with a maximum change of 136% at a dose of 6 g/d . Rodents, compared to humans, have higher requirements for the more highly unsaturated fatty acid DHA in their tissue phospholipids . This may preclude the need for higher levels of AA in tissues, accounting for the more modest effects observed in rodents following AA supplementation. Of importance, these changes in AA content were always at the expense of tissue LA, suggesting that dietary AA targets the same phospholipid pool occupied by LA [12, 32, 33]. This relationship between the changes in tissue levels of AA and LA following AA supplementation is supported by human clinical data . The inverse is not always true. While some studies suggest an inverse relationship exists between tissue LA and AA levels when LA is supplemented in the diet [11, 25, 28], these studies are in the minority.
Currently there are no guidelines providing assistance as to how to formulate a human equivalent diet for rodents to improve translation of data to humans. The overall intent of this research was to test a theoretical model for allometric scaling based on energy differences between species. We chose the relationship between dietary LA and its effects on tissue AA content as a testable target. We wanted to determine the extent to which supplementation with human equivalent doses of LA and AA changed tissue AA content within the context of a Western-type diet using a common experimental rodent model. We proposed that providing animals a background diet that mimicked the Western diet with regards to macro- and micronutrients and fatty acid profiles, and supplementing LA at human equivalent doses, we could observe a human equivalent response with regard to changes in AA levels in plasma/serum and erythrocyte phospholipids. Our results recapitulated those in humans and provide support for the concept that allometric scaling between species for dietary LA can be accomplished based on energy and metabolic differences. It is important to note that these results cannot be extrapolated to all tissues.
This research was funded in part by the Tennessee Agricultural Experiment Station, University of Tennessee, Knoxville, TN (JW).
dietary reference intake
essential fatty acid
human equivalent dose
polyunsaturated fatty acid
Wang D, Dubois RN: Prostaglandins and cancer. Gut. 2006, 55 (1): 115-122.
McEntee MF, Whelan J: Dietary polyunsaturated fatty acids and colorectal neoplasia. Biomed Pharmacother. 2002, 56 (8): 380-387.
Allayee H, Roth N, Hodis HN: Polyunsaturated fatty acids and cardiovascular disease: implications for nutrigenetics. J Nutrigenet Nutrigenomics. 2009, 2 (3): 140-148.
Whelan J, McEntee MF: Dietary (n-6) PUFA and intestinal tumorigenesis. J Nutr. 2004, 134 (12 Suppl): 3421S-3426S.
Buckman DK, Chapkin RS, Erickson KL: Modulation of mouse mammary tumor growth and linoleate enhanced metastasis by oleate. J Nutr. 1990, 120 (2): 148-157.
Igarashi M, Gao F, Kim HW, Ma K, Bell JM, Rapoport SI: Dietary n-6 PUFA deprivation for 15 weeks reduces arachidonic acid concentrations while increasing n-3 PUFA concentrations in organs of post-weaning male rats. Biochim Biophys Acta. 2009, 1791 (2): 132-139.
Mohrhauer H, Holman RT: The Effect of Dose Level of Essential Fatty Acids Upon Fatty Acid Composition of the Rat Liver. J Lipid Res. 1963, 4: 151-159.
Lokesh B, LiCari J, Kinsella JE: Effect of different dietary triglycerides on liver fatty acids and prostaglandin synthesis by mouse peritoneal cells. JPEN J Parenter Enteral Nutr. 1992, 16 (4): 316-321.
Mohrhauer H, Holman RT: Effect of Linolenic Acid Upon the Metabolism of Linoleic Acid. J Nutr. 1963, 81: 67-74.
Rahm JJ, Holman RT: Effect of Linoleic Acid Upon the Metabolism of Linolenic Acid. J Nutr. 1964, 84: 15-19.
Rett B, Whelan J: Increasing dietary linoleic acid does not increase tissue arachidonic acid content in adults consuming Western-type diets: a systematic review. Nutr Metab. 2011, 8: 36-
Petrik MB, McEntee MF, Johnson BT, Obukowicz MG, Whelan J: Highly unsaturated (n-3) fatty acids, but not alpha-linolenic, conjugated linoleic or gamma-linolenic acids, reduce tumorigenesis in Apc(Min/+) mice. J Nutr. 2000, 130 (10): 2434-2443.
Taber L, Chiu CH, Whelan J: Assessment of the arachidonic acid content in foods commonly consumed in the American diet. Lipids. 1998, 33 (12): 1151-1157.
Institute of Medicine FaNB: Dietary reference intakes for energy, carbohydrate, fiber, fat, fatty acids, cholesterol, protein, and amino acids. 2010, Washington, DC: National Academy Press
Dreyer G, Ray W, Ainley Walker EW: The Size of the Aorta in Warm-Blooded Animals and Its Relationship to the Body Weight and to the Surface Area Expressed in a Formula. Proc R Soc Lond B. 1912, 86: 39-56.
Dreyer G, Ray W, Ainley Walker EW: The Size of the Trachea in Warm-Blooded Animals, and Its Relationship to the Weight, the Surface Area, the Blood Volume, and the Size of the Aorta. Proc R Soc Lond B. 1912, 86: 56-65.
Krogh A: The respiratory exchange of animals and man. 1916, New York: Longmans, Green and Co
Kleiber M: Metabolic turnover rate: a physiological meaning of the metabolic rate per unit body weight. J Theor Biol. 1975, 53 (1): 199-204.
Blaxter SK: Bioenergetics and Growth: The Whole and the Parts. Journal of Animal Science. 1986, 63: 1-10.
Rucker R, Storms D: Interspecies comparisons of micronutrient requirements: metabolic vs. absolute body size. J Nutr. 2002, 132 (10): 2999-3000.
Rucker RB: Allometric scaling, metabolic body size and interspecies comparisons of basal nutritional requirements. J Anim Physiol Anim Nutr (Berl). 2007, 91 (3-4): 148-156.
Rett B, Whelan J: Increasing dietary linoleic acid does not increase tissue arachidonic acid content in adults consuming Western-type diets: a systematic review. In Review. 2011
Innis SM: Essential fatty acids in growth and development. Prog Lipid Res. 1991, 30 (1): 39-103.
Liou YA, King DJ, Zibrik D, Innis SM: Decreasing linoleic acid with constant alpha-linolenic acid in dietary fats increases (n-3) eicosapentaenoic acid in plasma phospholipids in healthy men. J Nutr. 2007, 137 (4): 945-952.
Angela Liou Y, Innis SM: Dietary linoleic acid has no effect on arachidonic acid, but increases n-6 eicosadienoic acid, and lowers dihomo-gamma-linolenic and eicosapentaenoic acid in plasma of adult men. Prostaglandins Leukot Essent Fatty Acids. 2009, 80 (4): 201-206.
Thijssen MA, Hornstra G, Mensink RP: Stearic, oleic, and linoleic acids have comparable effects on markers of thrombotic tendency in healthy human subjects. J Nutr. 2005, 135 (12): 2805-2811.
James MJ, Gibson RA, D'Angelo M, Neumann MA, Cleland LG: Simple relationships exist between dietary linoleate and the n-6 fatty acids of human neutrophils and plasma. Am J Clin Nutr. 1993, 58 (4): 497-500.
Adam O, Wolfram G, Zollner N: Influence of dietary linoleic acid intake with different fat intakes on arachidonic acid concentrations in plasma and platelet lipids and eicosanoid biosynthesis in female volunteers. Ann Nutr Metab. 2003, 47 (1): 31-36.
Lichtenstein AH, Matthan NR, Jalbert SM, Resteghini NA, Schaefer EJ, Ausman LM: Novel soybean oils with different fatty acid profiles alter cardiovascular disease risk factors in moderately hyperlipidemic subjects. Am J Clin Nutr. 2006, 84 (3): 497-504.
Demmelmair H, Iser B, Rauh-Pfeiffer A, Koletzko B: Comparison of bolus versus fractionated oral applications of [13C]-linoleic acid in humans. Eur J Clin Invest. 1999, 29 (7): 603-609.
Lin YH, Salem N: In vivo conversion of 18- and 20-C essential fatty acids in rats using the multiple simultaneous stable isotope method. J Lipid Res. 2005, 46 (9): 1962-1973.
Whelan J, Broughton KS, Surette ME, Kinsella JE: Dietary arachidonic and linoleic acids: comparative effects on tissue lipids. Lipids. 1992, 27 (1): 85-88.
Whelan J, Surette ME, Hardardottir I, Lu G, Golemboski KA, Larsen E, Kinsella JE: Dietary arachidonate enhances tissue arachidonate levels and eicosanoid production in Syrian hamsters. J Nutr. 1993, 123 (12): 2174-2185.
Li B, Birdwell C, Whelan J: Antithetic relationship of dietary arachidonic acid and eicosapentaenoic acid on eicosanoid production in vivo. J Lipid Res. 1994, 35 (10): 1869-1877.
Nelson GJ, Schmidt PC, Bartolini G, Kelley DS, Phinney SD, Kyle D, Silbermann S, Schaefer EJ: The effect of dietary arachidonic acid on plasma lipoprotein distributions, apoproteins, blood lipid levels, and tissue fatty acid composition in humans. Lipids. 1997, 32 (4): 427-433.
Thies F, Miles EA, Nebe-von-Caron G, Powell JR, Hurst TL, Newsholme EA, Calder PC: Influence of dietary supplementation with long-chain n-3 or n-6 polyunsaturated fatty acids on blood inflammatory cell populations and functions and on plasma soluble adhesion molecules in healthy adults. Lipids. 2001, 36 (11): 1183-1193.
Seyberth HW, Oelz O, Kennedy T, Sweetman BJ, Danon A, Frolich JC, Heimberg M, Oates JA: Increased arachidonate in lipids after administration to man: effects on prostaglandin biosynthesis. Clin Pharmacol Ther. 1975, 18 (5 Pt 1): 521-529.
Hulbert AJ, Rana T, Couture P: The acyl composition of mammalian phospholipids: an allometric analysis. Comp Biochem Physiol B Biochem Mol Biol. 2002, 132 (3): 515-527.
The authors declare that they have no competing interests.
KW conducted the research and co-wrote the manuscript, and JW formulated and designed the research, co-wrote the manuscript and had final responsibility for all parts of the manuscript. All authors have read and approved the final manuscript.